Allarity Therapeutics, Inc.
ALLR
$1.61
-$0.15-8.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.21% | 11.67% | 14.12% | -17.84% | 0.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.25% | 0.25% | 0.25% | -6,766.67% | -561.16% |
| Total Operating Expenses | 1.06% | -7.72% | 2.39% | -2.18% | 8.63% |
| Operating Income | -1.06% | 7.72% | -2.39% | 2.18% | -8.63% |
| Income Before Tax | -111.66% | -93.14% | -110.66% | -43.26% | 16.85% |
| Income Tax Expenses | -577.22% | -577.22% | -559.04% | 1.65% | 126.51% |
| Earnings from Continuing Operations | -106.98% | -88.86% | -105.99% | -44.30% | 14.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.98% | -88.86% | -105.99% | -44.30% | 14.45% |
| EBIT | -1.06% | 7.72% | -2.39% | 2.18% | -8.63% |
| EBITDA | -1.02% | 7.67% | -2.56% | 2.10% | -8.72% |
| EPS Basic | -193.98% | -- | -- | -- | -302.64% |
| Normalized Basic EPS | -8.87% | -- | -- | -- | -- |
| EPS Diluted | -193.98% | -- | -- | -- | -300.42% |
| Normalized Diluted EPS | -8.87% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 6,428.60% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 6,428.60% | -- | -- | -- | -93.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |